Blood test may forecast lung cancer return after surgery

NCT ID NCT07186855

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed study looked at 500 non-small cell lung cancer patients who had surgery. Researchers collected blood samples before and after surgery to detect circulating tumor cells (CTCs). They then analyzed these cells to see if their presence could predict cancer recurrence or survival. The goal is to improve follow-up care by identifying high-risk patients earlier.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this monitoring approach could help doctors better predict which lung cancer patients are at higher risk of recurrence after surgery.
What could go wrong
This is an observational study, not a treatment trial. The results may not lead to immediate changes in patient care, and the technology may not prove reliable enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Nationa Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, Beijingn, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.